Dipeptide Alanyl Glutamine and Postoperative Insulin Resistance in Colon Carcinoma Patients
N/A
18 Years
75 Years
18 Years
75 Years
Open (Enrolling)
Male
Colon Carcinoma
Male
Colon Carcinoma
Trial Information
Dipeptide Alanyl Glutamine and Postoperative Insulin Resistance in Colon Carcinoma Patients
Inclusion Criteria:
- Age between 18 and 75 years
- Colon cancer patients scheduled for elective open abdominal surgery
- Capable of giving informed consent
Exclusion Criteria:
- Patients who are participating in another clinical trial
- Unable to receive oral intake
- Major malabsorption disorder of the gut
- Patients with diabetes mellitus
- BMI above 30 kg/m2
- Use of certain medication: thyroid medication, corticosteroids, diuretic medication
- Known bleeding disorders or increased PTT and or APTT
- Any medical condition except for colon cancer
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention
Outcome Measure:
The effect of intravenously and enterally administered dipeptide alanyl-glutamine preoperatively on postoperative insulin resistance in colon cancer patients.given, on postoperative insulin resistance in colon cancer patients.
Outcome Time Frame:
Before and 1 day after surgery
Safety Issue:
No
Principal Investigator
Alexander PJ Houdijk, MD,PhD
Investigator Role:
Study Director
Investigator Affiliation:
MCA Alkmaar
Authority:
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Study ID:
AIRCo05.02.2009/2
NCT ID:
NCT00922688
Start Date:
December 2010
Completion Date:
May 2013
Related Keywords:
- Colon Carcinoma
- Dipeptide Alanyl-Glutamine
- Insulin sensitivity
- Intracellular signaling
- Antioxidant/oxidant parameters
- Lipolysis
- Inflammatory response in the liver
- Carcinoma
- Insulin Resistance
- Colonic Neoplasms
Name | Location |
|---|
